Atlas Trials

Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers

Clinical trial NCT05278195 · UNKNOWN

Trial details

NCT number
NCT05278195
Sponsor
Zhongda Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Hepatocellular Carcinoma
Start date
2022-04-01
Primary completion
2022-12-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.